Merck Group Expands India Peenya Facility to Strengthen Global Filtration Manufacturing
Published: 29 Apr 2026
Author: Towards Healthcare
Merck has expanded its manufacturing facility in Peenya, Bengaluru, adding new production lines for filtration hardware systems and Pellicon 2 Ultrafiltration Cassettes in 2026. Head of APAC Operations, Life Science Business, Merck, Tony Qiu, stated that these products are essential to producing life-saving medicines and vaccines.
By expanding manufacturing in India, we are strengthening global supply chains while also supporting local innovation and skills development.
According to Towards Healthcare, the virus removal filter system market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 4.72 billion in 2026 to approximately USD 14.06 billion by 2035, representing a compound annual growth rate (CAGR) of 12.9% from 2026 to 2035. Growth is driven by the increasing demand for sterile products in manufacturing and laboratory research, where stringent regulatory requirements for biopharmaceutical production are in place, with technological advancement leading to improved efficiency and cost-effectiveness.
Pellicon 2 ultrafiltration cassettes
It is widely used in bioprocessing and downstream purification workflows, supporting high-quality filtration across pharmaceutical and life sciences applications. Merck stated that the Peenya facility, which has served as a global hub for filtration hardware production since 2006, has steadily expanded its capabilities, including the addition of consumable manufacturing, such as prefilter cartridges, in 2022.
The latest expansion further reinforces India’s strategic importance in Merck’s global manufacturing network, aligning with the government’s 'Make in India' initiative to strengthen advanced manufacturing and local value creation in healthcare and life sciences.
A recent report by Towards Healthcare highlights that the virus removal filter system market is witnessing growth due to increasing global health concerns, technological advancements, and heightened awareness of air and water purification. This growth is influenced by factors such as increased regulatory standards, pandemic-driven demand, technological innovation, and rising consumer awareness regarding health and safety.
North America dominates the global market by increasing demand for biologics and vaccines, as well as the need for reliable virus clearance steps in the biopharmaceutical industry.
The Asia Pacific region is emerging as the fastest-growing market driven by increasing healthcare expenditures, expanding pharmaceutical manufacturing capabilities, and rising investments in biotechnology infrastructure.